Aemetis (NASDAQ:AMTX) Announces Earnings Results, Misses Estimates By $0.12 EPS

Aemetis (NASDAQ:AMTX) announced its quarterly earnings data on Thursday. The specialty chemicals company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.12), Zacks reports. The company had revenue of $59.19 million during the quarter, compared to analysts’ expectations of $87.79 million.

Aemetis Price Performance

Aemetis stock traded up $0.34 during trading hours on Friday, hitting $2.10. The stock had a trading volume of 1,324,071 shares, compared to its average volume of 999,169. Aemetis has a 1-year low of $1.22 and a 1-year high of $4.73. The stock has a market capitalization of $132.81 million, a price-to-earnings ratio of -1.30 and a beta of 1.73. The stock’s fifty day moving average is $2.45 and its two-hundred day moving average is $2.32.

Insider Activity at Aemetis

In related news, Director Francis P. Barton sold 26,452 shares of the business’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $2.53, for a total value of $66,923.56. Following the sale, the director directly owned 208,518 shares in the company, valued at $527,550.54. The trade was a 11.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 14.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Aemetis

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Aemetis by 15.3% in the third quarter. Vanguard Group Inc. now owns 2,479,163 shares of the specialty chemicals company’s stock valued at $5,578,000 after purchasing an additional 329,760 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Aemetis during the 2nd quarter worth approximately $634,000. Qube Research & Technologies Ltd acquired a new position in shares of Aemetis during the 2nd quarter worth approximately $246,000. Goldman Sachs Group Inc. lifted its stake in Aemetis by 71.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 218,404 shares of the specialty chemicals company’s stock valued at $380,000 after buying an additional 91,367 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in Aemetis by 412.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 80,754 shares of the specialty chemicals company’s stock valued at $200,000 after buying an additional 65,010 shares in the last quarter. 27.02% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Ascendiant Capital Markets boosted their target price on shares of Aemetis from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, October 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aemetis in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Aemetis currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.